1187586-61-3

Basic information

• Product Name: Montelukast Bis-sulfide (Mixture of Diastereomers)
• Synonyms: 1-[[[(1R)-1-[3-[(1R)-1-[[[1-(CarboxyMethyl)cyclopropyl]Methyl]thio]-2-(7-chloro-2-quinolinyl)ethyl]phenyl]-3-[2-(1-hydroxy-1-Methylethyl)phenyl]propyl]thio]Methyl]-cyclopropaneacetic Acid;2-(1-((((R)-1-(3-((R)-1-(((1-(carboxymethyl)cyclopropyl)methyl)thio)-2-(7-chloroquinolin-2-yl)ethyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propyl)thio)methyl)cyclopropyl)acetic acid;(R,R)-Montelukast Bis-sulfide;Montelukast Michael Adducts (mixture of diastereomers);Montelukast Bis-sulfide (Mixture of Diastereomers);Montelukast Michael Adduct R,R-IsoMer;Montelukast Bis-sulfide;Montelukast Sodium EP impurity D
• CAS NO: 1187586-61-3
• Molecular Formula: C₄₁H₄₆ClNO₅S₂
• Molecular Weight: 732.39064
• Product Categories: Aromatics;Heterocycles;Impurities;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds
• Mol File: 1187586-61-3.mol
• Article Data: 2

Chemical Properties

• Melting Point: 53-60°C
• Boiling Point: 856.9±65.0 °C(Predicted)
• Appearance: /
• Density: 1.302±0.06 g/cm3(Predicted)
• Storage Temp.: Refrigerator
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 4.76±0.10(Predicted)
• CAS DataBase Reference: Montelukast Bis-sulfide (Mixture of Diastereomers)(CAS DataBase Reference)
• NIST Chemistry Reference: Montelukast Bis-sulfide (Mixture of Diastereomers)(1187586-61-3)
• EPA Substance Registry System: Montelukast Bis-sulfide (Mixture of Diastereomers)(1187586-61-3)

Safety Data

• Hazardous Substances Data: 1187586-61-3(Hazardous Substances Data)

Usage

Description

Montelukast Bis-sulfide (Mixture of Diastereomers) is a pale yellow solid that is an impurity of Montelukast and is a part of the diastereomer mixture Montelukast Bis-Sulfide (M567985). It is also known as Montelukast EP Impurity D and Montelukast USP Related Compound C.

Uses

Used in Pharmaceutical Industry:
Montelukast Bis-sulfide (Mixture of Diastereomers) is used as a Montelukast impurity in the pharmaceutical industry. It is important to monitor and control the levels of this impurity in Montelukast to ensure the safety and efficacy of the drug.

Upstream product

• 287930-77-2 (S,E)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propan-1-ol 
• 181139-72-0 methyl-[(E)]-2-[3(S)-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-hydroxypropyl] benzoate 
• 149968-11-6 methyl 2-(3-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-oxopropyl)benzoate 
• 1197414-05-3 C₂₉H₂₆ClNO 
• 869066-93-3 (S)-1-(3-((E)-2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl acetate 
• 1197374-10-9 (S)-1-(3-((E)-2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-isopropenylphenyl)propan-1-ol hydrochloride 
• 152922-73-1 2-[1-(mercaptomethyl)cyclopropyl]acetic acid methyl ester 
• 807638-71-7 2-[2-[3(S)-[3-[(1E)-2-(7-chloroquinoline-2-yl)ethenyl]phenyl]-3-methanesulfonyloxypropyl]phenyl]-2-propanol 
• 1197374-12-1 [1-[(R)-1-(3-[(E)-2-(7-chloroquinolin-2-yl)vinyl]-phenyl)-3-(2-isopropenylphenyl)propylsulfanylmethyl]cyclopropyl]acetic acid dicyclohexylamine salt 
• 1197374-09-6 (S)-1-(3-((E)-2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-isopropenylphenyl)propyl acetate 
• 1197374-11-0 (S)-1-(3-((E)-2-(7-chloroquinolin?2-yl)vinyl)phenyl)-3-(2-isopropenylphenyl)propyl methanesulphonate 
• 1351973-24-4 C₄₁H₄₄ClNO₄S₂ 
• 918972-54-0 [R-(E)]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-[1-(1-methyl)ethenyl]phenyl]propyl]thio]methyl]cyclopropaneacetic acid 
• 162515-68-6 1-(sulfanylmethyl)cyclopropaneacetic acid 

Relevant articles and documents

Identification, synthesis and characterization of impurities of Montelukast sodium

Montelukast sodium is a selective leukotriene receptor antagonist which inhibits cysteinyl leukotriene CysLT1 receptor. Various synthesis of Montelukast is published. During laboratory optimization and later in bulk synthesis formation of various impurities was detected. Besides, pharma Europa draft mention nine process related impurities. However, the method of preparation of most of these impurities is not available in literature. Also, different route of synthesis will have different impurity profile and those process related impurities are not covered in pharmacopeias. In this study we report the synthesis of possible process impurities, including seven impurities (A-H) mentioned in pharma Europa.